FOR DISTRIBUTION TO UK CONSUMER MEDIA ONLY (EXCLUDING REPUBLIC OF IRELAND AND MEDICAL MEDIA) Adherence is a significant challenge for patients living with psoriasis (studies consistently suggest that ...

LEO Pharma has launched Enstilar, billing it as the first fixed-combination foam spray for psoriasis treatment in the UK - and said it is more effective than other combination treatments. Psoriasis is ...

Please provide your email address to receive an email when new articles are posted on . LEO Pharma announced in a press release that Enstilar has received scientific approval in the E.U. for treating ...

Trials show that the foam, called Enstilar, is more effective than traditional creams and ointments. More than half of trial patients with the skin condition are said to have experienced significant ...

Licence marks first combination foam spray for plaque psoriasis: Enstilar ® (calcipotriol/betamethasone dipropionate) 50 micrograms/g + 0.5mg/g cutaneous foam LEO ...

LEO Pharma today announced that it received scientific approval of Enstilar ® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment ...

Adult patients with plaque psoriasis have gained a new treatment option in the UK following the launch of LEO Pharma's Enstilar, the first fixed-combination, cutaneous foam spray for topical ...

LEO Pharma has received scientific approval for Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis vulgaris ...

Please provide your email address to receive an email when new articles are posted on . LEO Pharma announced in a press release that Enstilar has been approved by the FDA for the topical treatment of ...

The marketing approval of Enstilar(R) would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU. LEO Pharma today announced that it received ...